198 related articles for article (PubMed ID: 15553393)
1. Piercing the veil of corporate secrecy about clinical trials.
Lemmens T
Hastings Cent Rep; 2004; 34(5):14-8. PubMed ID: 15553393
[No Abstract] [Full Text] [Related]
2. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
3. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
4. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
5. Study critiques corporate control of trials.
Niiler E
Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
[No Abstract] [Full Text] [Related]
6. Clinical trials in India: balancing economic opportunity with the public health context.
Dandona L
Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189
[No Abstract] [Full Text] [Related]
7. Drive for drugs leads to baby clinical trials.
Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
[No Abstract] [Full Text] [Related]
8. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
9. Patients, physicians, and clinical trials: the other side of the coins.
Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
[No Abstract] [Full Text] [Related]
10. Trading on traditional medicines.
Basu P
Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
[No Abstract] [Full Text] [Related]
11. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
12. Stocks' study renews concerns over insider trading on oncology drugs.
Goozner M
J Natl Cancer Inst; 2011 Nov; 103(22):1652-5. PubMed ID: 22025626
[No Abstract] [Full Text] [Related]
13. Who pays what in drug development.
Love J
Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
[No Abstract] [Full Text] [Related]
14. Industry reneges on postmarketing trial commitments.
Bouchie A
Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
[No Abstract] [Full Text] [Related]
15. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
16. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
17. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
18. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
19. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
20. Wall Street and clinical trials.
Steinbrook R
N Engl J Med; 2005 Sep; 353(11):1091-3. PubMed ID: 16162879
[No Abstract] [Full Text] [Related]
[Next] [New Search]
